KROMATID Unveils Genomic Intelligence Platform to Enhance Cell Therapy Development
KROMATID has announced a significant advancement in genomic integrity assessment, which will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The company is introducing a genomic intelligence platform that establishes chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies. This platform aims to provide integrated, decision-ready insights, moving beyond fragmented assays. By leveraging high-depth cytogenetic analysis and a structured dataset, KROMATID enables benchmarking of cell therapies against chromosome-level standards, offering greater confidence in safety, quality, and development decisions. 
